

Janice M Reichert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7372228/publications.pdf>

Version: 2024-02-01

66
papers

9,229
citations

76326

40
h-index

54911

84
g-index

111
all docs

111
docs citations

111
times ranked

10202
citing authors

#	ARTICLE	IF	CITATIONS
1	Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery, 2010, 9, 767-774.	46.4	873
2	Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery, 2019, 18, 585-608.	46.4	755
3	Monoclonal antibody successes in the clinic. Nature Biotechnology, 2005, 23, 1073-1078.	17.5	682
4	Future directions for peptide therapeutics development. Drug Discovery Today, 2013, 18, 807-817.	6.4	633
5	Antibodies to watch in 2019. MAbs, 2019, 11, 219-238.	5.2	387
6	Antibodies to watch in 2020. MAbs, 2020, 12, 1703531.	5.2	381
7	Development trends for monoclonal antibody cancer therapeutics. Nature Reviews Drug Discovery, 2007, 6, 349-356.	46.4	359
8	Marketed therapeutic antibodies compendium. MAbs, 2012, 4, 413-415.	5.2	320
9	Recombinant protein therapeuticsâ€™ success rates, market trends and values to 2010. Nature Biotechnology, 2004, 22, 1513-1519.	17.5	286
10	Development trends for therapeutic antibody fragments. Nature Biotechnology, 2009, 27, 331-337.	17.5	262
11	Antibodies to watch in 2022. MAbs, 2022, 14, 2014296.	5.2	239
12	Antibodies to watch in 2021. MAbs, 2021, 13, 1860476.	5.2	237
13	Monoclonal Antibodies as Innovative Therapeutics. Current Pharmaceutical Biotechnology, 2008, 9, 423-430.	1.6	235
14	Antibodies to watch in 2017. MAbs, 2017, 9, 167-181.	5.2	225
15	Antibodies to watch in 2018. MAbs, 2018, 10, 183-203.	5.2	223
16	Trends in development and approval times for new therapeutics in the United States. Nature Reviews Drug Discovery, 2003, 2, 695-702.	46.4	214
17	Antibody-based therapeutics to watch in 2011. MAbs, 2011, 3, 76-99.	5.2	207
18	Marketing approval of mogamulizumab. MAbs, 2012, 4, 419-425.	5.2	193

#	ARTICLE	IF	CITATIONS
19	Antibodies to watch in 2016. MAbs, 2016, 8, 197-204.	5.2	163
20	Monoclonal antibodies in the clinic. Nature Biotechnology, 2001, 19, 819-822.	17.5	162
21	Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs, 2011, 3, 415-416.	5.2	156
22	Antibodies to watch in 2015. MAbs, 2015, 7, 1-8.	5.2	149
23	Antibody-drug conjugates. MAbs, 2014, 6, 15-17.	5.2	131
24	Development trends for new cancer therapeutics and vaccines. Drug Discovery Today, 2008, 13, 30-37.	6.4	120
25	The future of antibodies as cancer drugs. Drug Discovery Today, 2012, 17, 954-963.	6.4	115
26	Approval of the first biosimilar antibodies in Europe. MAbs, 2013, 5, 621-623.	5.2	114
27	Which are the antibodies to watch in 2013?. MAbs, 2013, 5, 1-4.	5.2	107
28	Monoclonal antibodies market. Nature Reviews Drug Discovery, 2004, 3, 383-384.	46.4	98
29	Antibodies to watch in 2014. MAbs, 2014, 6, 5-14.	5.2	90
30	Antibodies to watch in 2010. MAbs, 2010, 2, 84-100.	5.2	86
31	Antibodies to watch in 2013. MAbs, 2013, 5, 513-517.	5.2	71
32	Metrics for antibody therapeutics development. MAbs, 2010, 2, 695-700.	5.2	70
33	Which are the antibodies to watch in 2012?. MAbs, 2012, 4, 1-3.	5.2	65
34	Total Syntheses of (+)-Acutiphycin and (+)-trans-20,21-Didehydroacutiphycin. Journal of the American Chemical Society, 1995, 117, 12013-12014.	18.7	60
35	New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999. Trends in Biotechnology, 2000, 18, 364-369.	9.3	57
36	Anti-infective monoclonal antibodies: perils and promise of development. Nature Reviews Drug Discovery, 2006, 5, 191-195.	46.4	54

#	ARTICLE	IF	CITATIONS
37	Total Syntheses of (+)-Acutiphycin and (+)-trans-20,21-Didehydroacutiphycin. <i>Journal of the American Chemical Society</i> , 1997, 119, 10935-10946.	13.7	48
38	Antibodies to watch in 2014. <i>MAbs</i> , 2014, 6, 799-802.	5.2	41
39	Trends in US approvals: new biopharmaceuticals and vaccines. <i>Trends in Biotechnology</i> , 2006, 24, 293-298.	9.3	32
40	Public and Private Sector Contributions to the Discovery and Development of ???Impact??? Drugs. <i>American Journal of Therapeutics</i> , 2002, 9, 543-555.	0.9	28
41	Therapeutic monoclonal antibodies: trends in development and approval in the US. <i>Current Opinion in Molecular Therapeutics</i> , 2002, 4, 110-8.	2.8	25
42	Global antibody development trends. <i>MAbs</i> , 2009, 1, 86-87.	5.2	22
43	Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections. <i>BioDrugs</i> , 2007, 21, 1-7.	4.6	21
44	Bispecific antibodies and ADCs. <i>MAbs</i> , 2011, 3, 329-330.	5.2	15
45	Probabilities of success for antibody therapeutics. <i>MAbs</i> , 2009, 1, 387-389.	5.2	13
46	Clinical development of therapeutic recombinant proteins. <i>BioTechniques</i> , 2003, 35, 176-185.	1.8	11
47	Biopharmaceuticals approved in the EU 1995â€“1999: a European Unionâ€“United States comparison. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2001, 51, 1-7.	4.3	10
48	Therapeutic cancer vaccines on trial. <i>Nature Biotechnology</i> , 2002, 20, 659-663.	17.5	10
49	The amazing, multipurpose antibody. <i>MAbs</i> , 2011, 3, 221-222.	5.2	10
50	IBCâ€™s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5â€“8, 2011, San Diego, CA. <i>MAbs</i> , 2012, 4, 153-181.	5.2	10
51	Clinical Development of Therapeutic Medicines: A Biopharmaceutical Versus Pharmaceutical Product Comparison. <i>Drug Information Journal</i> , 2001, 35, 337-346.	0.5	9
52	mAb therapeutic products and risk management. <i>MAbs</i> , 2010, 2, 1-2.	5.2	9
53	The Effects of the Prescription Drug User Fee Act and the Food and Drug Administration Modernization Act on the Development and Approval of Therapeutic Medicines. <i>Drug Information Journal</i> , 2001, 35, 85-94.	0.5	7
54	7th Annual European Antibody Congress 2011. <i>MAbs</i> , 2012, 4, 134-152.	5.2	7

#	ARTICLE	IF	CITATIONS
55	Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA. MAbs, 2016, 8, 617-652.	5.2	7
56	A decade of the Fast Track programme. Nature Reviews Drug Discovery, 2008, 7, 885-886.	46.4	5
57	Letter from the Editor. MAbs, 2010, 2, 107-107.	5.2	3
58	Note of appreciation to reviewers. MAbs, 2017, 9, 1-4.	5.2	3
59	Editorial for PEDS special issue on antibodies. Protein Engineering, Design and Selection, 2010, 23, 153-154.	2.1	2
60	Progress atmAbs. MAbs, 2010, 2, 593-593.	5.2	1
61	Antibody Engineering and Therapeutics Conference. MAbs, 2013, 5, 817-825.	5.2	1
62	Letter from the Editor. MAbs, 2009, 1, 91-92.	5.2	0
63	Letter from the Editor. MAbs, 2009, 1, 189-189.	5.2	0
64	mAbs™s communication networks. MAbs, 2012, 4, 133-133.	5.2	0
65	Note of appreciation to reviewers. MAbs, 2015, 7, 281-285.	5.2	0
66	Note of appreciation to reviewers. MAbs, 2016, 8, 653-657.	5.2	0